Transdermal testosterone

Drugs

Volumn 55, Issue 2, 1998, Pages 253-258

  McClellan, Karen J ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ESTRADIOL; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AROUSAL; BLISTER; CIRCADIAN RHYTHM; CLINICAL TRIAL; ERYTHEMA; ESTRADIOL BLOOD LEVEL; HUMAN; HYPOGONADISM; LONG TERM CARE; LUTEINIZING HORMONE BLOOD LEVEL; MALE; META ANALYSIS; ORGASM; PROSTATE; PRURITUS; REVIEW; SEXUAL BEHAVIOR; SEXUAL FUNCTION; TESTOSTERONE BLOOD LEVEL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031914789     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855020-00006     Document Type: Review

References (17)

1. Mazer NA, Heiber WE, Moellmer JF, et al. Enhanced transdermal delivery of testosterone: A new physiological approach for androgen replacement in hypogonadal men. J Control Release 1992; 19 (1-3): 347-61
2. Mazer NA. Enhanced transdermal delivery of testosterone and other drugs [abstract]. Int Pharm J 1991; 5 Suppl. 1: 10
3. Cofrancesco J, Jr, Dobs AS. Transdermal testosterone delivery systems. Endocrinologist 1996 May; 6: 207-13
4. Arver S, Dobs AS, Meikle AW, et al. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996 May; 155: 1604-8
5. Arver S, Dobs AS, Meikle AW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol. In press
6. Meikle AW, Mazer NA, Moellmer JF, et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992 Mar; 74: 623-8
7. Meikle AW, Arver S, Dobs AS, et al. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site - a clinical research center study. J Clin Endocrinol Metab 1996 May; 81: 1832-40
8. Brocks DR, Meikle AW, Boike SC, et al. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose. J Clin Pharmacol 1996 Aug; 36: 732-9
9. Meikle AW, Wilson DE, Bolke SC, et al. A study to assess the bioequivalence of Androderm® (2 × 2.5 mg patches) and a newly formulated testosterone transdermal system (1 × 5 mg patch) [abstract]. 79th Annual Meeting of the Endocrine Society; 1997 Jun 11-14: Minneapolis, 321
10. Prescribing information: Androderm® testosterone transdermal controlled-delivery for once-daily application. Available from: URL: http://www.androderm.com/prescribe.htm1#-prescribe [Accessed 1997 Jul 24]
11. Meikle AW, Annand D, Hunter C, et al. Pre-treatment with a topical corticosteroid cream improves local tolerability and does not significantly alter the pharmacokinetics of the Androderm® testosterone transdermal system in hypogonadal men [abstract]. 79th Annual Meeting of the Endocrine Society; 1997 Jun 11-14; Minneapolis, 322
12. Meikle AW, Arver S, Dobs AS, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997 Feb; 49: 191-6
13. Meikle AW, Arver S, Dobs AS, et al. Safety of testosterone transdermal system used to treat hypogonadal men for up to 4 years [abstract]. 10th International Congress of Endocrinology 1996 Jun 12; 1: 175
14. Wilson DE, Kaidbey K, Boike SC, et al. Use of topical corticosteroid cream in the pretreatment of skin reactions associated with Androderm® testosterone transdermal system [abstract]. 79th Annual Meeting of the Endocrine Society; 1997 Jun 11-14; Minneapolis, 323
15. Behre HM, Bohmeyer J, Nieschlag N. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol 1994 Mar; 40: 341-9
16. Meikle AW, Arver S, Dobs AS, et al. Effects of a permeation-enhanced testosterone transdermal system on prostate parameters in previously treated or untreated hypogonadal males [abstract]. Br J Urol 1496 Jun; 77 Suppl. 1: 38
17. Arver S, Meikle AW, Dobs AS, et al. Hypogonadal men treated with the Androderm® testosterone transdermal system had fewer abnormal hematocrit elevations than those treated with testosterone enanthate injections [abstract no. P327]. In: The Endocrine Society. 79th Annual Meeting Program and Abstracts: 1997 Jun 11-14: Minneapolis